ESTRAGUARD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTRAGUARD (ESTRAGUARD).
Estradiol, the active ingredient, binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene transcription and exerting estrogenic effects including endometrial growth, vasodilation, and bone protection.
| Metabolism | Primarily hepatic via CYP3A4 and CYP1A2; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates (glucuronides and sulfates). |
| Excretion | Estradiol and its metabolites are primarily excreted in urine (approximately 90-95%), with about 5% excreted in feces via bile. Less than 10% is excreted unchanged. |
| Half-life | The terminal elimination half-life of estradiol is approximately 13-20 hours following transdermal administration, allowing for twice-weekly dosing. Oral estradiol has a shorter half-life of 2-4 hours due to first-pass metabolism. |
| Protein binding | Approximately 98% bound, primarily to sex hormone-binding globulin (SHBG) (30-50%) and albumin (30-50%). Unbound fraction is about 2%. |
| Volume of Distribution | Transdermal estradiol has a volume of distribution of approximately 1.2 L/kg, indicating extensive distribution into tissues. Oral estradiol has a Vd of about 1.4 L/kg. |
| Bioavailability | Oral: Approximately 2-10% due to extensive first-pass metabolism. Transdermal: 3-10% (systemic), but consistent delivery avoids first-pass. Vaginal: Absorption is variable; for local effects, systemic bioavailability is low (approximately 5% for cream), but for systemic replacement, vaginal ring achieves ~50% bioavailability. |
| Onset of Action | Transdermal: Symptom relief (e.g., hot flashes) typically occurs within 2-4 weeks. Oral: Onset of action is within 2-4 weeks for menopausal symptoms. Vaginal: Local effects (e.g., vaginal atrophy) may improve within 7-10 days. |
| Duration of Action | Transdermal: Duration of action is approximately 3-4 days, supporting twice-weekly application. Oral: Duration of action is about 24 hours, requiring daily dosing. Vaginal: Local effects last 24 hours for cream; ring provides 3 months of continuous release. |
| Molecular Weight | 272.38 |
0.1% cream: 2-4 g intravaginally once daily for 2 weeks, then 1-2 g once daily 1-3 times per week for maintenance. Estradiol vaginal ring: 2 mg releasing 7.5 mcg/24h, inserted vaginally every 90 days.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. GFR <30 mL/min: use with caution due to potential fluid retention. |
| Liver impairment | Child-Pugh class A/B: no adjustment. Child-Pugh class C: contraindicated due to reduced estradiol metabolism. |
| Pediatric use | Not indicated in pediatric patients. |
| Geriatric use | Initiate at lowest effective dose; use non-oral route if risk of thromboembolism. Monitor for endometrial hyperplasia if uterus intact; consider progestin coadministration. |
| 1st trimester | Contraindicated due to risk of fetal harm; estrogen exposure in first trimester associated with congenital anomalies including cardiovascular and genitourinary defects. |
| 2nd trimester | Avoid use; estrogens can affect fetal development and increase risk of adverse outcomes. |
| 3rd trimester | Not recommended; estrogens may cause fetal feminization and other developmental issues. |
Clinical note
Comprehensive clinical and safety monograph for ESTRAGUARD (ESTRAGUARD).
| Placental transfer | Estradiol and its derivatives cross the placenta readily; fetal serum levels can approach maternal levels with chronic use. |
| Breastfeeding | Estradiol is excreted into human breast milk in small amounts, but no adverse effects have been reported in nursing infants. However, because it may reduce milk production and composition, caution is advised. |
■ FDA Black Box Warning
Estrogens should not be used to prevent cardiovascular disease or dementia. In the Women’s Health Initiative (WHI) study, increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis were reported. In the Women’s Health Initiative Memory Study (WHIMS), increased risk of probable dementia was observed in postmenopausal women 65 years of age or older.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive or history of venous thromboembolismActive or history of arterial thromboembolic diseaseRenal impairment (creatinine clearance < 30 mL/min)Liver dysfunction or disease
| Precautions | Increased risk of endometrial cancer; use with progestin in women with intact uterus, Increased risk of cardiovascular events (stroke, MI, DVT, PE), Increased risk of probable dementia in women ≥65 years, Gallbladder disease, Hypertriglyceridemia, Retinal vascular thrombosis, Fluid retention, Hypocalcemia in pre-existing hypoparathyroidism, Exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Estraguard (estradiol) is contraindicated in pregnancy. First trimester: Estrogens are associated with a risk of congenital anomalies including cardiovascular defects and urogenital malformations; also linked to vaginal adenosis and clear cell adenocarcinoma in female offspring with in utero DES exposure. Second and third trimesters: Continued exposure may increase risk of fetal reproductive tract abnormalities, low birth weight, and preterm delivery; no safe dose established; risk category X. |
| Fetal Monitoring | If inadvertent use occurs during pregnancy: Perform detailed fetal anatomical ultrasound including cardiac evaluation. Monitor fetal growth with serial ultrasounds. Assess for signs of estrogen-related adverse effects. No routine monitoring recommended for lactating infants beyond standard pediatric care if brief exposure. |
| Fertility Effects | Estradiol may suppress ovulation in a dose-dependent manner, potentially reducing fertility; use as a contraceptive is not approved. Fertility may be impaired during therapy but is generally reversible upon discontinuation; no permanent adverse effect on fertility expected. |
| No specific food interactions known. Grapefruit juice may slightly increase estradiol levels but not clinically significant with vaginal ring. |
| Clinical Pearls | ESTRAGUARD (estradiol vaginal ring) releases estradiol locally; systemic absorption is minimal but measurable. For vaginal atrophy, it is as effective as creams but with less mess and once-daily dosing. If the ring expels, rinse with lukewarm water and reinsert. Do not use in women with undiagnosed vaginal bleeding or active thromboembolic disorder. Monitor for breast tenderness and endometrial hyperplasia in prolonged use. |
| Patient Advice | To insert the ring, compress it and push gently into the upper third of the vagina. · Replace the ring every 90 days (3 months). · If the ring falls out, rinse with water and reinsert; if it cannot be retained, consult your healthcare provider. · Do not use oil-based lubricants with the ring as they may degrade it. · Report any unusual vaginal bleeding or pelvic pain promptly. · The ring does not protect against sexually transmitted infections. |